| Revue: | Revista médica de Chile |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000454991 |
| ISSN: | 0034-9887 |
| Autores: | Triantafilo, Nicolás1 Sarmiento, Mauricio1 Campbell, James1 Rojas, Patricio1 García, María José1 Sandoval, Vicente1 Bertín, Pablo1 Ocqueteau, Mauricio1 Risueño, María Concepciãn2 Rodríguez, Isabel2 Galleguillos, Mauricio2 |
| Instituciones: | 1Red de Salud UC-Christus, Hematología, Santiago de Chile. Chile 2Red de Salud UC-Christus, Laboratorio de Hematología, Santiago de Chile. Chile |
| Año: | 2022 |
| Periodo: | May |
| Volumen: | 150 |
| Número: | 5 |
| Paginación: | 643-649 |
| País: | Chile |
| Idioma: | Español |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Acute myeloid leukemia (AML) is the most common leukemia in adults. Aim: To Describe our population of patients with AML and report the outcomes of our treatments. Material and Methods: Review of electronic clinical records of 114 patients with AML with a median age of 57 years (59% men). Results: Seventeen percent of patients were classified as low risk, 38% as intermediate risk and 33% as high risk. Seventy-six percent of patients were treated with intensive chemotherapy. Five years overall survival according to cytogenetic risk was 59, 41, and 12% in low, intermediate, and high-risk patients, respectively. The outcomes were better in patients under 60 years. The median survival of patients treated with intensive chemotherapy aged less than 60 years and 60 years and above was 3.4 and 1 year, respectively. Conclusions: Our results are comparable to those reported in developed countries. Improving the survival of patients 60 years and older is our main challenge |
| Disciplinas: | Medicina |
| Palabras clave: | Hematología, Leucemia mieloide aguda, Epidemiología, Chile |
| Keyword: | Hematology, Acute myeloid leukemia, Epidemiology, Chile |
| Texte intégral: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
